Big Wins and Setbacks in Pharma and Defense | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded08 Sep 2026

Publisherfeeds.acast.com ↗

Handlerec:20295577

Show notes

Roivant Sciences scores a major win as Pulmovant’s Phase Two trial shows real lung resistance drops for pulmonary hypertension patients. Meanwhile, Lockheed Martin gets a boost from UBS’ upgraded rating, while Novartis hits a snag with del-desiran failing in Phase Three for myotonic dystrophy. Peloton takes a hit as Morgan Stanley downgrades due to fitness industry headwinds, and Boston Scientific warns of 2026 sales and profit impacts after a cyberattack. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/327359530498b0ed

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.